NeuBase Therapeutics logo

NeuBase TherapeuticsNASDAQ: NBSE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

28 May 2004

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$1.41 M
-99%vs. 3y high
4%vs. sector
-vs. 3y high
-vs. sector
-94%vs. 3y high
18%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 24 May 2024 13:30:00 GMT
$0.38(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

Included in screeners

No data

NBSE Latest News

Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?
InvestorPlace26 March 2024 Sentiment: NEGATIVE

NeuBase Therapeutics (NASDAQ: NBSE ) stock is falling on Tuesday after the company announced details for an upcoming special shareholder meeting. The big news here is that NeuBase Therapeutics is seeking shareholder approval for the liquidation and dissolution of the company.

NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake
Zacks Investment Research07 September 2023 Sentiment: POSITIVE

With NeuBase (NBSE) exploring strategic alternatives to the company, Symetryx joins the company's shareholder base and urges the board to issue a unique $1 per share dividend.

Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?
InvestorPlace06 September 2023 Sentiment: POSITIVE

NeuBase Therapeutics (NASDAQ: NBSE ) stock is taking off on Wednesday despite a lack of news from the preclinical biopharmaceutical company. There are no new press releases from NeuBase Therapeutics or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.

What type of business is NeuBase Therapeutics?

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

What sector is NeuBase Therapeutics in?

NeuBase Therapeutics is in the Healthcare sector

What industry is NeuBase Therapeutics in?

NeuBase Therapeutics is in the Biotechnology industry

What country is NeuBase Therapeutics from?

NeuBase Therapeutics is headquartered in United States

When did NeuBase Therapeutics go public?

NeuBase Therapeutics initial public offering (IPO) was on 28 May 2004

What is NeuBase Therapeutics website?

https://www.neubasetherapeutics.com

Is NeuBase Therapeutics in the S&P 500?

No, NeuBase Therapeutics is not included in the S&P 500 index

Is NeuBase Therapeutics in the NASDAQ 100?

No, NeuBase Therapeutics is not included in the NASDAQ 100 index

Is NeuBase Therapeutics in the Dow Jones?

No, NeuBase Therapeutics is not included in the Dow Jones index

When does NeuBase Therapeutics report earnings?

Next earnings report date is not announced yet